COVAXIN shows 78% clinical and 100% efficacy against severe COVID-19
The COVAXIN developed and manufactured by Bharat Biotech, “neutralizes multiple variants of SARS-COV-2 and effectively neutralises the double mutant strain as well,” the ICMR statement.
According to the Indian Council of Medical Research on Wednesday said Covaxin has shown an overall interim clinical efficacy of 78% and a 100% efficacy against severe Covid-19 disease. The efficacy was announced on the basis of a second interim analysis after more than 87 symptomatic cases of Covid-19 were reported among the Phase 3 trials volunteers of Covaxin.
In recent years, diet and lifestyle have been recognized as crucial factors influencing cancer risk.…
Surgical advancements have evolved significantly over the decades, leading to improved precision, reduced recovery time,…
A tragic incident in northwest Delhi has sparked a medical negligence controversy after a 20-year-old…
Maharashtra is set to witness a significant transformation in its public health sector with the…
Sleep is essential for overall health, yet many people suffer from sleep disorders that disrupt…
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…